表紙
市場調查報告書

慢性阻塞性肺病 (COPD) - 至2023年的流行病學的預測

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 347928
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
慢性阻塞性肺病 (COPD) - 至2023年的流行病學的預測 Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028
出版日期: 2019年12月31日內容資訊: 英文 38 Pages
簡介

由於 慢性阻塞性肺病 (COPD) ,是引起呼吸困難和呼吸急促、喘鳴、胸部壓迫感等症狀的疾病,根據WHO認為到2030年成為第3大死因。在全球8大市場中,慢性阻塞性肺病的患病數量預計從2013年的約6,423萬件以年率1.49%擴大,2023年增加到7,380萬。

本報告提供慢性阻塞性肺病的概要與風險因素、全球8大市場的趨勢,以及今後的流行病學的預測彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
  • 全球的趨勢
    • 美國
    • 歐洲5個國家
    • 日本及澳洲
  • 預測方法
    • 使用的資訊來源
    • 未使用的資訊來源
    • 預測方法與假設
  • 流行病學的預測
    • 患病數量
    • 各年齡患病數量
    • 性別患病數量
    • 年齡標準化數量
    • 各重度數量
    • 確診數量
    • 各年齡確診數量
    • 性別確診數量
    • 年齡評估確診數量
    • 各重度確診數量
    • 有共生病症的確診數量
    • 存活1年的確診數量
  • 考察
    • 流行病學的預測
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER228-19

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms. The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017). Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for COPD was based on symptoms and the results of spirometry testing. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. GlobalData epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in GlobalData's forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope

  • The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ≥35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
  • The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
  • Understand magnitude of COPD population by severity at diagnosis.

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Chronic Obstructive Pulmonary Disease (COPD): Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for COPD (2018-2028)
    • 3.5.1 Total Prevalent Cases of COPD
    • 3.5.2 Sex-Specific Total Prevalent Cases of COPD
    • 3.5.3 Age-Specific Total Prevalent Cases of COPD
    • 3.5.4 Diagnosed Prevalent Cases of COPD
    • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.7 Diagnosed Prevalent Cases of COPD by Severity
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for COPD

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years, 2018 and 2028
  • Figure 3: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 4: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
  • Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
  • Figure 8: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 9: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 10: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 11: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 12: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 13: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 14: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 15: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 16: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018